FLZ decreased the expression of BACE1 and did not affect the expression of IDE. by Xiu-Qi Bao (479278)

Mice deficient in P2Y₁₂ are protected from global cerebral ischemia and also have decreased microglia surrounding areas of injury. by Corey M. Webster (442040)

“…<p>Following bilateral common carotid artery occlusion for 12 min followed by 3 d reperfusion, P2Y₁₂ deficient mice (P2Y₁₂^+/−) suffered less injury to hippocampal CA1 compared to wildtype (WT) mice. …”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Deletion of TXNIP decreases nitrative stress under normoxia and hyperoxia. by Mohammed A. Abdelsaid (287140)

Deletion of TXNIP decreases thioredoxin levels under hyperoxic conditions. by Mohammed A. Abdelsaid (287140)

“…<p>WT and TKO mice were subjected to 5 days hyperoxia (p7–12). …”

Expression of neurabin and spinophilin in the mouse brain at 4 and 12 months of age. by Huiying Wu (1587136)

Decreased virulence observed during <i>in planta</i> infection with <i>ΔFgknr4</i>. by Erika Kroll (20537020)

“…<p><b>A.</b> Wheat spike infection assay done on the susceptible cultivar Bobwhite point inoculated with sterile water only (M), wild-type <i>F</i>. …”

HO-1 decreased tubulointerstitial inflammation in the UUO model. by Xiao Chen (260187)

Detailed meta–analyses in untreated hypothyroid patients compared with controls for each HRV parameters: RR intervals, SDNN, RMSSD, pNN50, TP, LF, HF, LF/HF. by Valentin Brusseau (12769704)

Decreased CCL2 levels protect A20^AEC-KO mice against influenza A infection by Jonathan Maelfait (181048)

In-silico SHH KO results show a decrease in cytokines as comared to WT. by Shruti Marwaha (654096)

Neutralization potency decreases 6-months post 2^nd vaccine but breadth and potency increase after a 3^rd vaccine dose. by Carl Graham (9415779)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

The 12 kinds of surfactants selected in the experiment. by Xinhui Luo (11880086)

In-phase (A) and opposed phase (B) chemical shift MR images of a 51-year-old male demonstrate hepatic steatosis, consistent with areas of decreased signal intensity on an opposed-p... by Andrzej Cieszanowski (635105)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…GCase activity measured by 4-MU in liver (B) measured as follows: WT 4mo 93.69±7.16, HOM 4mo 3.90±0.21, WT 8mo 112.40±6.84, HOM 8mo 1.50±0.19, WT 12 mo 96.79±7.44, HOM 12mo 3.50±0.58. …”

Treatment with a highly reducing agent decreases ubiquitination of D_4.2R WT and D_{4.2 4KR}R mutant. by Kamila Skieterska (841014)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)